NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Eupraxia Pharmaceuticals Inc. (EPRX) Stock Analysis

Eupraxia Pharmaceuticals Inc. (EPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

EPRX

$8.40

+$0.90 (+12.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EPRX with… →

EPRX Key Statistics

As of Sep 4, 2026
Trading
Open
$7.45
Previous Close
$7.50
Day's Range
7.39–8.40
52-Week Range
5.15–9.32
Volume
3.52M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.49
Valuation
Market Cap
$555.02M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.14
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$38.58M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.07M
1-Year Return
+56.72%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
379.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EPRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+11.26%
2025+138.17%
2024 (partial year)+7.46%

As of September 4, 2026.

EPRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$38.58M—
2024$0.00−$25.50M—
2023$0.00−$28.22M—
2022$0.00−$18.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.43M−$38.58M—
2024$0.00—−$27.00M−$25.50M—
2023$0.00—−$27.85M−$28.22M—
2022$0.00—−$17.62M−$18.49M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EPRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricEPRXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Eupraxia Pharmaceuticals Inc. (EPRX) carries a market capitalisation of $555.02M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 49 employees.

The most recent close on file for EPRX is $8.40, dated September 4, 2026. That is +$0.90 (+12.00%) against the previous close. Over the past 52 weeks the price has ranged from $5.15 to $9.32. The latest close sits 63.11% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $38.58M. The reported profit margin is 0%. Trailing earnings per share are −1.14.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +56.72%. The stored price history starts on April 5, 2024, and the total return since then is +184.75%. The reported beta is 1.49. Daily returns over the trailing 2 years annualize to a volatility of 65.89%.

Growth & Income

No dividend is on file for EPRX.

2026 is still running; the price is +11.26% year to date. The record holds one complete calendar year, 2025, which returned +138.17%.

Peer Comparison

Eupraxia Pharmaceuticals Inc. (EPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eupraxia Pharmaceuticals Inc. EPRX $555.02M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Eupraxia Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Visit website →